Tirzepatide (Mounjaro) currently delivers the strongest blood sugar lowering of any weekly injectable for type 2 diabetes, reducing HbA1c by up to 2.30% in clinical trials. Semaglutide (Ozempic) is a close second at 1.86% and has more long-term cardiovascular data behind it. The “best” option depends on your blood sugar goals, weight loss priorities, heart health history, insurance coverage, and how your body handles side effects.
Weekly Injectables Available Now
Three weekly injections are widely prescribed for type 2 diabetes. Each works by mimicking gut hormones that signal your pancreas to release insulin when blood sugar rises, slow digestion, and reduce appetite.
- Tirzepatide (Mounjaro) targets two gut hormone pathways simultaneously, which is why it produces larger reductions in both blood sugar and body weight than single-pathway drugs.
- Semaglutide (Ozempic) targets one of those same pathways and has been on the market longer, with extensive cardiovascular safety data.
- Dulaglutide (Trulicity) works through the same single pathway as semaglutide but is generally considered slightly less potent. It remains a solid option for people who respond well to it or whose insurance favors it.
A once-weekly insulin (icodec) has also completed late-stage trials and is entering markets in some countries. It matches the blood sugar control of daily basal insulin but carries a higher rate of low blood sugar episodes, roughly double in clinical trials. It’s designed for people who already need insulin, not as a first-line injectable.
Blood Sugar Control: How They Compare
In the head-to-head SURPASS-2 trial, tirzepatide lowered HbA1c by 2.01% at its lowest dose (5 mg), 2.24% at 10 mg, and 2.30% at its highest dose of 15 mg. Semaglutide at 1 mg lowered HbA1c by 1.86% in the same trial. That gap of roughly 0.15 to 0.44 percentage points may sound small, but for someone starting with an HbA1c of 8.5% or higher, it can be the difference between reaching target and not.
Real-world data has generally confirmed this advantage, though the differences outside of controlled trials tend to be smaller. In one study of patients switching from other injectables, tirzepatide produced an additional 0.43% HbA1c drop at 12 weeks compared to 0.36% for semaglutide. Both drugs are meaningfully more effective than older options like dulaglutide.
Weight Loss Differences
Weight loss matters for diabetes management because losing even 5 to 10% of body weight improves insulin sensitivity and can reduce the need for additional medications. All three weekly injectables cause some weight loss by slowing stomach emptying and reducing appetite, but tirzepatide produces significantly more. In trials, people on tirzepatide lost roughly 12 to 25 pounds on average depending on the dose, while semaglutide users lost around 10 to 15 pounds. Dulaglutide typically produces more modest weight loss of 5 to 8 pounds.
Heart and Kidney Benefits
Weekly injectables in this drug class do more than lower blood sugar. A large meta-analysis of placebo-controlled trials found that these medications reduce major cardiovascular events (heart attack, stroke, or cardiovascular death) by 14% overall. The benefit held across subgroups: people with and without existing heart disease, those with higher and lower BMI, and both men and women.
The cardiovascular protection extended to specific outcomes as well. All-cause mortality dropped by 13%, cardiovascular death by 13%, and non-fatal stroke by 13%. Fatal stroke risk fell by 26%. Kidney outcomes also improved, with a 24% reduction in a broad composite measure of kidney disease progression.
Most of this evidence comes from trials of semaglutide and liraglutide (a daily injectable in the same class). Tirzepatide’s dedicated cardiovascular outcomes trial is still ongoing, so while early signals are promising, semaglutide currently has the stronger evidence base for heart protection specifically. If you have existing heart disease or are at high cardiovascular risk, this distinction matters when choosing between the two.
Side Effects and Tolerability
Stomach-related side effects are the main downside of all weekly injectables in this class. Across clinical trials, 40 to 70% of patients experience some combination of nausea, vomiting, diarrhea, or constipation, though these symptoms are usually worst during the first few weeks of treatment and when doses increase. For semaglutide at the diabetes dose (1 mg weekly), nausea affects 15 to 24% of users and vomiting 7 to 15%. Tirzepatide has similar rates.
Every one of these medications uses a gradual dose-escalation schedule to minimize gut side effects. You start at the lowest dose and increase every four weeks, giving your body time to adjust. Eating smaller meals, avoiding high-fat foods, and stopping eating when full (rather than when the plate is empty) all help during the adjustment period. Most people find the nausea manageable and that it fades within the first month or two at each dose level.
More serious but rare concerns include inflammation of the pancreas and, in animal studies, thyroid tumors. These medications are not recommended for people with a personal or family history of a specific type of thyroid cancer called medullary thyroid carcinoma.
What the Injections Feel Like
All three weekly injectables come in pre-filled pen devices that you use at home. The needles are very fine, typically 31 to 32 gauge and only 4 to 6 mm long. Most people describe the injection as a brief pinch or say they barely feel it. You inject into your stomach, thigh, or upper arm, rotating sites each week.
You can give yourself the shot on the same day each week, at any time of day, with or without food. If you miss your usual day, most pens allow you to take it within a few days and then resume your regular schedule.
Storage and Handling
Unused pens need to be kept in the refrigerator (36°F to 46°F). Once you start using a pen, or if you need to travel, it can stay at room temperature (up to 86°F) for up to 30 days. After 30 days at room temperature, the pen should be discarded even if medication remains. Never freeze these pens, and keep them out of direct sunlight.
Cost Without Insurance
Cost is often the deciding factor. Without insurance or discount programs, Ozempic (semaglutide) runs roughly $1,000 to $1,200 per month, adding up to over $12,000 a year. Mounjaro (tirzepatide) falls in a similar range. Trulicity (dulaglutide) can be somewhat less expensive but still costs hundreds per month at retail price.
All three manufacturers offer savings cards that can significantly reduce out-of-pocket costs for commercially insured patients, sometimes bringing copays down to $25 per month. If you’re uninsured, manufacturer patient assistance programs and pharmacy discount tools like GoodRx can lower the price, though availability changes frequently. Your insurance formulary, meaning which drugs your plan prefers, often matters more than the clinical differences between these medications. A drug your insurer covers at a lower tier will almost always be cheaper than one that requires prior authorization or sits on a higher cost tier.
Choosing Between Them
If your primary goal is the largest possible drop in blood sugar and body weight, tirzepatide has the edge in clinical data. If you have established heart disease or high cardiovascular risk and want the most proven protection, semaglutide currently has stronger evidence. If cost or insurance coverage is the main constraint, whichever medication your plan covers best is a reasonable choice, since all three are effective.
Some people try one medication, experience persistent side effects, and do better after switching to another in the same class. The gut hormone pathways these drugs target overlap but aren’t identical, so tolerability can vary from person to person. Starting with the option your insurance prefers and switching if needed is a practical strategy that most endocrinologists support.